Compare CSBR & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSBR | CING |
|---|---|---|
| Founded | 1985 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4M | 70.2M |
| IPO Year | 2015 | 2021 |
| Metric | CSBR | CING |
|---|---|---|
| Price | $4.75 | $4.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $21.20 |
| AVG Volume (30 Days) | 6.8K | ★ 114.5K |
| Earning Date | 12-14-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,900,000.00 | N/A |
| Revenue This Year | $9.83 | N/A |
| Revenue Next Year | $8.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.59 | $3.16 |
| 52 Week High | $8.31 | $11.89 |
| Indicator | CSBR | CING |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 36.16 |
| Support Level | $4.71 | $4.19 |
| Resistance Level | $5.17 | $5.31 |
| Average True Range (ATR) | 0.21 | 0.31 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 29.84 | 3.50 |
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.